MHB018A Treatment in Patients With Chronic Thyroid Eye Disease

Summary

The primary objective of this study is to investigate the efficacy, safety, and tolerability of MHB018A, a humanized anti-IGF1R antibody, administered Q4W for 6 months, in comparison to placebo, in the treatment of participants suffering from chronic TED.

Timeline

Start

2026-03-17

Primary completion

2027-08-31

Completion

2028-08-31

Drugs

Indications